Experts' recommendations for treating maladaptive aggression in youth

Journal of Child and Adolescent Psychopharmacology

Volumn 21, Issue 6, 2011, Pages 505-515

  Pappadopulos, Elizabeth ^a   Rosato, Nancy Scotto ^b   Correll, Christoph U ^c   Findling, Robert L ^d   Lucas, Judith ^b   Crystal, Stephen ^b   Jensen, Peter S ^e,f  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e REsource for Advancing Children's Health   (United States)

^f MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM; RISPERIDONE; VALPROATE SEMISODIUM;

AGGRESSION; ARTICLE; BEHAVIOR THERAPY; CLINICAL DECISION MAKING; HUMAN; MALADJUSTMENT; OUTPATIENT CARE; PARENT COUNSELING; PEDIATRICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHIATRIC TREATMENT; QUESTIONNAIRE; SOCIAL PSYCHOLOGY;

ADOLESCENT; AGGRESSION; CHILD; CONSENSUS; DATA COLLECTION; HUMANS; PSYCHOTHERAPY; PSYCHOTROPIC DRUGS;

EID: 84555196297     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2010.0128     Document Type: Article

References (25)

1. Brook RH, Chasin MR, Fink A, Solomon DH, Kosecoff J, Park RE: A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care 2:53-63, 1986.
2. Cheung AH, Zuckerbrot RA, Jensen PS, Ghalib K, Laraque D, Stein RKE: Guidelines for adolescent depression in primary care (GLAD-PC):II. Treatment and ongoing management. Pediatrics 120:e1313-e1326, 2007. (Pubitemid 350085548)
3. Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA: New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med 158:753-759, 2004. (Pubitemid 39025073)
4. Correll CU: Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 47:9-20, 2008.
5. Crystal S, Olfson M, Huang C, Pincus H, Gerhard T: Broadened use of atypical antipsychotics: Safety, effectiveness, and policy challenges. Health Aff (Millwood) 28:770-781, 2009.
6. Findling RL, Aman MG, Eerdekens M, Derivan A, Lyons B: Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 161: 677-684, 2004. (Pubitemid 38445512)
7. Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt D, Binder C: Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 64:1362-1369, 2003. (Pubitemid 37490243)
8. Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH: A multiple-center, randomized, double-blind, placebo-controlled study of oral ar-ipiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 165:1432-1441, 2008.
9. Findling RL, Kauffman R, Sallee FR, Salazar DE, Sahasrabudhe V, Kollia G, Kornhauser DM, Vachharajani N, Assuncao-Talbott S, Mallikaarjun S, Iwamoto T, McQuade RD, Boulton DW, Blumer J: An open-label study of aripiprazole: Pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder. J Child Adolesc Psychopharmacol 19:431-439, 2009.
10. Jensen P, Builtelaar J, Pandina G, Binder R, Reyes M: Management of psychiatric disorders in children and adolescents with atypical antipsychotics. Eur J Child Adolesc Psychiatry 16:104-120, 2007a.
11. Jensen PS, Youngstrom E, Steiner H, Findling RL, Meyer RE, Malone RP, Carlson GA, Coccaro EF, Aman MG, Blair J, Dougherty D, Ferris C, Flynn L, Green E, Hoagwood K, Hutchinson J, Laughren T, Leve LD, Novins DK, Vitiello B: Consensus report: Impulsive aggression as a symptom across diagnostic categories in child psychiatry: Implications for medication studies. J Am Acad Child Adolesc Psychiatry 46:309-322, 2007b.
12. Khan DA, Docherry JP, Carpenter D, Frances A: Consensus methods in practice guidelines development: A review and description of a new method. Psychopharmacol Bull 33:631-639, 1997. (Pubitemid 28128115)
13. Martin A, Leslie D: Psychiatric inpatient, outpatient, and medication utilization and costs among privately insured youths, 1997-2000. Am J Psychiatry 160:757-764, 2003. (Pubitemid 41079610)
14. Mojtabai R, Olfson M: National trends in psychotherapy by office-based psychiatrists. Arch Gen Psychiatry 65:962-970, 2008.
15. Olfson M, Blanco C, Liu L, Moerno C, Laje G: National trends in outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 63:679-685, 2006. (Pubitemid 43848299)
16. Olfson M, Crystal S, Huang C, Gerhard T: Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry 49:13-23, 2010.
17. Pappadopulos E, MacIntyre JC II, Crismon ML, Findling RL, Malone RP, Derivan A, Schooler A, Sikich L, Greenhill LL, Schur SB, Felton C, Kranzler H, Rube D, Sverd J, Finnerty M, Ketner S, Siennick SE, Jensen PS: Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY): Part Two. J Am Acad Child Adolesc Psychiatry 42:145-161, 2003. (Pubitemid 39610594)
18. Pappadopulos E, Woolston S, Chait A, Perkins M, Connor DF, Jensen PS: Pharmacotherapy of aggression in children and adolescents: Efficacy and effect size. J Can Acad Child Adolesc Psychiatry 15:27-39, 2006.
19. Patel NC, Crismon ML, Hoagwood K, Jensen PS: Unanswered questions regarding antipsychotic use in children and adolescents. J Child Adolesc Psychopharmacol 15:270-284, 2005a. (Pubitemid 40734106)
20. Patel NC, Crismon ML, Hoagwood K, Johnsrud MT, Rascati KL, Wilson JP, Jensen PS: Trends in the use of atypical and typical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 44:548-556, 2005b. (Pubitemid 40720954)
21. Pliszka SR, Crismon ML, Hughes CW, Conners CK, Emslie GJ, Jensen PS, McCracken JT, Swanson JM, Lopez M, Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder: The Texas Children's Medication Algorithm Project: A revision of the algorithm for medication treatment of childhood attention deficit hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry 45:520-526, 2006.
22. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, et al.: Weight gain associated with olanzapine and risperidone in adolescent patients: A comparative prospective study. J Am Acad Child Adolesc Psychiatry 41:337-343, 2002. (Pubitemid 38338156)
23. Reyes et al.: A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 163:402-410, 2006. (Pubitemid 44469381)
24. RUPP Autism Network: Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 162:1361-1369, 2005.
25. Schur SB, Sikich L, Findling RL, Malone RP, Crismon ML, Derivan A, MacIntyre JC, II, Pappadopulos E, Greenhill LL, Schooler N, Van Order K, Jensen PS: Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY) Part One: A review. J Am Acad Child Adolesc Psychiatry 42:132-144, 2003. (Pubitemid 39610593)